Baillie Gifford & CO Nektar Therapeutics Transaction History

Baillie Gifford & CO

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 19, 2021	SELL	$13.07 - $18.84 $2,169 - $3,127	-166 Reduced 10.77%	1,376 $25,000
Q1 2021 May 06, 2021	BUY	$16.56 - $25.46 $513 - $789	31 Added 2.05%	1,542 $31,000
Q4 2020 Feb 10, 2021	BUY	$15.77 - $19.03 $23,828 - $28,754	1,511 New	1,511 $26,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

Stay updated on Baillie Gifford & CO with notifications on news.